Background: Targeted intraoperative radiation therapy (IORT) as an alternative to whole breast irradiation (WBI) has been described for patients with early
Introduction
Breast conservation therapy consisting of breastconserving surgery followed by postoperative whole breast irradiation is considered the current standard of practice for patients with early-stage breast cancer. 1 Several randomized trials have demonstrated equivalent overall survival for patients who undergo breast conservation therapy vs mastectomy. [2] [3] [4] Whole breast irradiation is administered in the postoperative setting as 45 Gy to 50 Gy in daily fractions for 5 consecutive weeks. An additional external beam boost of 10 Gy to 16 Gy is often delivered to the tumor bed to further improve local control and decrease local recurrence rates. 5 
Rationale for APBI
While overall outcomes are highly favorable for patients who undergo breast conservation therapy with external beam irradiation, there is growing interest in alternative irradiation fractionation regimens. These alternative modalities could provide similar local control while sparing normal breast parenchyma, thereby improving cosmesis. Additionally, daily round-trips for up to 6 weeks may be fi nancially and physically prohibitive for many women. Accelerated partial breast irradiation (APBI) techniques, delivered as 3D conformal external beam radiotherapy, as intraoperative radiotherapy (IORT), or as interstitial/intracavitary implants have been evaluated in multiple clinical trials as alternatives to conventional whole breast irradiation. [6] [7] [8] [9] Support for the use of APBI comes from the observation that 80% to 90% of local recurrences following whole breast irradiation occur in proximity to the original tumor bed. [10] [11] [12] APBI offers several theoretical advantages over whole breast irradiation, including (1) decreased radiation dose to uninvolved portions of the breast and surrounding normal organs such as the heart and lungs, and (2) shortened treatment courses from 5 to 6 weeks to 5 days or less, allowing many women who could not undergo a conventional postoperative radiotherapy course due to socioeconomic constraints or comorbidities to choose breast conservation therapy over mastectomy. 10, 11, 13, 14 
Patient Selection Criteria for APBI
All patients considered for APBI should be suitable candidates for breast conservation therapy with earlystage invasive breast cancer and low risk of clinically occult disease remote from the lumpectomy cavity. Initial early APBI experiences were complicated by unacceptably high local recurrence rates, possibly related to suboptimal patient selection and/or treatment technique. [15] [16] [17] [18] [19] More recently accepted stringent criteria would have rendered many of these early patients unsuitable candidates for APBI therapy. While local recurrence rates have dramatically decreased over the last decade, the lessons observed from these early pioneering studies highlight several of the tumor-, treatment-, and patient-related factors that warrant mentioning when considering potential eligibility for APBI.
Primary Tumor Characteristics
Primary tumor size (pT) is a signifi cant determinant of patients who might be considered for APBI therapy. Early APBI studies included patients with tumor sizes ranging from 0 cm to 5 cm; the larger sizes (4 cm to 5 cm) may have contributed to higher local recurrences. [16] [17] [18] 20 The more recent trend has been to treat smaller primary tumors, ranging in diameter of 0 cm to 3 cm. [21] [22] [23] [24] Additionally, larger tumors (> 3 cm) have been found to have a higher incidence of late softtissue toxicity (ie, fat necrosis) impacting cosmesis, quality of life, and imaging requirements -another reason they may be less ideal candidates for APBI. 25 Thus patients with primary T3 or T4 tumors should not undergo breast conservation therapy with APBI.
Multicentricity, defi ned as the presence of tumor foci more than 2 cm from the primary lesion, is associated with an increased risk of local recurrence and is another contraindication to APBI. 16, 18 The extent of disease cannot be assessed or adequately treated using current APBI techniques. Multifocal tumors, however, defi ned as separate foci within the same quadrant, potentially may be treated. While a majority of prospective single-arm APBI trials have not considered multifocality as an eligibility criterion, a limited number of centers have included patients with multifocal (unicentric) tumors. [26] [27] [28] The American Society for Radiation Oncology (ASTRO) Task Force considers patients with multifocality measuring < 2 cm as "suitable" for APBI, whereas those with multifocality measuring < 3 cm as "cautionary" and > 3 cm as "unsuitable" for APBI. 29 Histologic grade has not been routinely included as a selection criterion in a majority of the prospective APBI studies performed thus far. The centers that have specifi cally addressed histologic grade have limited enrollment to low-or intermediate-grade (I or II) tumors. 10, [21] [22] [23] [24] The Hungarian randomized trial of APBI vs whole breast irrdiation demonstrated that histologic grade had no signifi cant impact on long-term control but that those with high-grade (III) tumors did have a shorter time to local recurrence (20 months) than those with low-or intermediate-grade (I-II) tumors (38 months) . 30, 31 Others have demonstrated tumor grade to be a strong predictor of local recurrence. 12 While data remain limited on the long-term outcome of high-grade tumors treated with APBI, the ASTRO consensus statement lists "any" tumor grade as "suitable" criteria for APBI. 29 
Surgical Margin of Resection
A positive surgical margin is a major determinant of risk of local recurrence after breast-conserving therapy. 32, 33 Five-year local failure rates are better for those with clear (negative) margins (0%) than for those with close (4%), focal (6%), or diffusely positive margins (21%). 33 However, data are limited regarding the surgical margin of resection, measured from the inked surgical margin to the nearest invasive or associated in situ component, for patients considered for APBI. Early APBI studies allowed patients with unknown or focally positive margins, which may have contributed to higher local recurrences. 15, 17, 18, 20, 34 Recent studies have used more stringent requirements, including clear (negative) margins as a selection criterion. 24, 26, 35, 36 Limited clinical data are available for patients with negative but close (< 2 mm) surgical margins. Nonetheless, several centers have begun to offer APBI to patient with close margins (negative but tumor within 2 mm to 5 mm) with acceptable local recurrences and long-term follow-up. 8, 22, 23, 27, 28, 37 Histology Invasive lobular carcinoma histology has been largely considered a relative contraindication to APBI due to its multifocal nature and diffuse pattern of spread. In the Christie Hospital study, local recurrence rates as high as 43% were reported for patients with invasive lobular cancer who received radiotherapy only to the tumor bed. 16 Authors of the German-Austrian multicenter APBI trial, however, reported no signifi cant difference in 5-year local recurrence rates between invasive lobular cancer and other histologies. 23 The consensus Task Force recommendation from ASTRO recommends that patients with invasive lobular histology be considered "cautionary" for undergoing APBI as clinical data are limited. 29 Lobular carcinoma in situ has largely not been regarded as a separate component of the eligibility criteria in most prospective single-arm APBI trials.
On the contrary, patients with ductal carcinoma in situ (DCIS) have largely been excluded from prospective single-arm APBI trials and therefore limited clinical information is available. 7, 21, 28 Many of these tumors are multifocal and widespread (extensive disease), both of which are signifi cant predictors of local recurrence. 38 However, some radiation oncologists treat small (< 3 cm) unifocal DCIS tumors excised with adequate margins. 26 The Task Force recommendation is that small DCIS tumors be included in the "cautionary" group, whereas those with more extensive DCIS should be considered "unsuitable" for APBI. 29 Patients whose primary tumors contain an extensive intraductal component (consisting of more than 25% of an intraductal carcinoma or DCIS component) are also generally not recommended to undergo treatment with APBI, the rationale being that tumors with extensive intraductal components behave similarly to pure DCIS tumors. The American Society of Breast Surgeons (ASBS) MammoSite APBI trial registry demonstrated a higher association of ipsilateral breast tumor recurrence (IBTR) in patients with an extensive intraductal component. 39 For this reason, most authors consider extensive intraductal component a contraindication to APBI.
Patient Age
Studies have demonstrated that patients aged 60 years or greater have a lower incidence of IBTR and that younger patient age is a signifi cant adverse prognostic factor for local recurrence. 5, [40] [41] [42] [43] For these reasons, most prospective APBI trials defi ned eligibility as women 50 years of age or greater. Many of the early APBI trials originally had no patient age selection criteria or included patients > 40 years, which also may have contributed to the early unacceptably high local recurrence rates observed in those series. 16, 17, 20, 44 More recent prospective APBI trials have demonstrated lower local recurrence rates for patients who were treated at 60 years of age or greater (1.8% to 6.7%) than those at 40 years or greater (2.6% to 19%). 24, 28, 37, 45 Taken together, these studies offer confl icting results for patients < 50 years of age. Further prospective studies and additional follow-up are needed to clarify the role of APBI for this target age population (40 to 60 years of age). 46 The ASTRO consensus guideline considers age 50 to 59 years as a cautionary criterion and age < 50 as unsuitable. However, the European Society for Therapeutic Radiology and Oncology (ES-TRO) guidelines allow age > 50 as "good candidates" and age > 40 to 50 as "possible candidates," with only age ≤ 40 considered a contraindication.
Other Considerations
The majority of the patients treated with APBI have had estrogen receptor (ER)-positive tumors and are thus considered "suitable" based on the ASTRO consensus statement for APBI. 29 While several European and American APBI studies have enrolled hormone receptor-negative patients, several studies have demonstrated higher local recurrence with ER-or progesterone-negative tumor status. Despite these negative results for hormone receptor-negative tumors, a lack of a consensus treating these tumors still exists. [47] [48] [49] HER2 expression status also remains controversial, as many studies predate the era of routine HER2 testing, and this parameter is not discussed in either the ASTRO or ESTRO guidelines. HER2 overexpression has been associated with higher local recurrence rates without the use of systemic trastuzumab. 50 While further study is required, APBI should perhaps be offered only to patients with HER2 overexpression if they are receiving systemic therapy including trastuzumab and who also meet suitability criteria.
Due to the lack of existing data, the Task Force recommendation for patients with a personal or family history of BRCA1 or BRCA2 mutation is that they do not receive APBI outside of a clinical trial. 29 Candidates for APBI should undergo axillary staging with sentinel lymph node biopsy or level I/II axillary dissection. Patients with positive lymph nodes are at a higher risk of local-regional recurrence and distant failure, and they are contraindicated for APBI consideration. 1, 29 A majority of prospective APBI studies have enrolled only pathologically node-negative patients, which is the current recommendation for consideration of APBI. Those patients with isolated tumor cells (< 0.2 mm) should be considered node-negative. 51 The European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) and ASTRO Task Force consensus panels have described characteristics for patients considered to be "low-risk, intermediate-risk, high-risk" and/or "suitable, cautionary, or unsuitable" for APBI, respectively. A brief comparison of the GEC-ESTRO and ASTRO guidelines is described in Tables 1-3 .
APBI Techniques
APBI is a form of radiotherapy that delivers daily fraction doses of radiation greater than 2 Gy, delivered in less than or equal to 5 days. Unlike whole breast irradiation, which treats the entire breast, APBI treats only the lumpectomy cavity and a surrounding 1 cm to 2 cm margin of breast parenchyma. A variety of APBI techniques are currently in clinical use today and differ in their method of radiation delivery, biological effective radiation dose, and clinical application. Additional experience and follow-up from prospective clinical trials will provide further insight on the long-term outcome on local control, cosmesis, and clinical impact of these APBI therapies.
Multicatheter Interstitial Brachytherapy
Multicatheter interstitial brachytherapy was the fi rst APBI technique described and has had the longest follow-up with respect to newer modalities. 26 It was initially developed as a boost technique to be delivered after whole breast irradiation. Multicatheter interstitial brachytherapy is an invasive technique that requires precise placement of multiple fl exible after-loading catheters into the tumor bed either free-handed or using a template guide. The catheters, up to 14 to 20 in number, are placed in parallel planes, approximately 10 mm to 20 mm apart, to ensure adequate lumpectomy cavity coverage. Computed tomography guidance and virtual planning have had a signifi cant impact on catheter placement and treatment planning. 52 Irradiation is administered either as low dose rate (LDR) or high dose rate (HDR) brachytherapy. 
Treatment Factors
Neoadjuvant therapy Not allowed Not allowed * Mucinous, tubular, medullary and colloid allowed. ** Based on sentinel lymph node biopsy or axillary lymph node dissection. LVSI = lymphovascular space invasion, EIC = extensive intraductal component, DCIS = ductal carcinoma in situ, LCIS = lobular carcinoma in situ. 
Neoadjuvant therapy Not allowed Not allowed * ILC, mucinous, tubular, medullary and colloid allowed. ** Based on axillary lymph node dissection. LVSI = lymphovascular space invasion, EIC = extensive intraductal component, DCIS = ductal carcinoma in situ, LCIS = lobular carcinoma in situ.
LDR requires inpatient admission and delivers 45 Gy over 3 to 5 days, whereas an HDR implant may be performed on an outpatient basis, administering 32 Gy to 34 Gy in 8 to 10 fractions (twice daily for 4 to 5 days). 26, 53 Multicatheter interstitial brachytherapy has several advantages over other APBI techniques. The fl exibility of the multicatheter method allows precise conformation to the anatomical shape and location of the irradiated target volume cavity. This method also has the longest reported experience of any other APBI technique, and long-term cosmetic results have been favorable. 54, 55 Excellent long-term local control rates (> 5 years) have been reported among several institutions, ranging from 1% to 6%. 4, 26, [35] [36] [37] [56] [57] [58] While these long-term results are encouraging, the widespread adoption of interstitial brachytherapy use has been limited to only a few centers because of the expertise required to perform this technique and the technical diffi culties associated with its application.
MammoSite Balloon Catheter
The MammoSite catheter (Hologic Inc, Marlborough, MA) is a balloon-based brachytherapy device placed within the lumpectomy cavity at the time of surgery (or as a separate procedure after surgery) and was approved by the US Food and Drug Administration (FDA) in 2002 as a single interstitial balloon catheter alternative to multicatheter interstitial brachytherapy. 59 The catheter consists of a double lumen catheter with a balloon at the end and is easier to handle with a shorter learning curve. 60 The balloon is infl ated (30-cc to 70-cc volume) with a mixture of contrast and saline to conform to the lumpectomy cavity. Brachytherapy is administered via an HDR source introduced within the inner lumen of the catheter to the center of the balloon surface. Irradiation therapy is given in an outpatient manner, twice a day, over 5 days with a minimum of 6 hours between treatments. At completion of the last treatment, the balloon is defl ated and the catheter is removed.
Outcome results for APBI using the MammoSite catheter have generally been favorable; local recurrence rates range between 0% to 5.7% with an intermediate length of follow-up (20 to 60 months). 7, 22, 28, [61] [62] [63] Vicini et al 64 reported on 1,440 patients enrolled in the ASBS breast brachytherapy registry trial. Thirty-seven cases (2.6%) of IBTR were observed with a median follow-up of 60 months, an actuarial 5-year IBTR rate of 3.8%. Negative hormone receptor status was associated with an increased risk of IBTR for those with invasive carcinoma, while age (< 50 years) and positive margin were associated with increased IBTR for DCIS.
Cosmetic results have been reported by several contemporary clinical studies using the MammoSite catheter and are improved by proper patient selection with good or excellent cosmetic outcomes observed in 84% to 95% of cases. 6, 61, 64, 65 Maintaining a balloon catheter-to-skin distance of at least 7 mm is recommended and is associated with a greater improvement in cosmesis. 22, 65 Maintaining the required skin-to-balloon cavity distance may be more diffi cult in tumors situated in the upper-inner quadrant or small volume breast. Short-term toxicity with the MammoSite balloon catheter has been associated with erythema, edema, and pain. 59 Symptomatic seroma is the most frequently reported long-term toxicity associated with MammoSite catheter use. Persistent seroma rates as high as 50% to 72% have been reported in some smaller series. 6, 66 The incidence of clinically significant seroma is higher with associated infection and may be reduced with prophylactic antibiotics. 67 The ASBS MammoSite registry trial of 1,449 cases reported a 90.6% good or excellent cosmetic outcome, with an incidence of symptomatic breast seroma formation in 13% and long-term fat necrosis in 2.3%. 
Contura Multiple Lumen Balloon Catheter
The Contura balloon catheter (SenoRx Inc, Aliso Viejo, CA) differs from the MammoSite catheter in that it has multiple (four) lumens that allow passage of an iridium-192 HDR source. The Contura device contains 4 lumens, fi xed at 5 mm from a central channel, that allow passage of the HDR source and conform to the lumpectomy cavity. 68 A vacuum port is present on the catheter that allows removal of air or fl uid around the lumpectomy cavity, resulting in reproducible radiation dose delivery and increased target volume coverage. 69 The Contura catheter was approved by the FDA in 2007. Early clinical experience showed that the Contura catheter was well tolerated, with 100% good/excellent cosmetic outcome and 3% symptomatic seroma formation observed during short follow-up of 8 months. 70 Three-year follow-up data have been reported, with a 2% local recurrence rate and 4.3% symptomatic seroma rate, both similar to other APBI alternatives of similar follow-up (median of 36 months).
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Hybrid Brachytherapy Devices
ClearPath Brachytherapy System ClearPath (North American Scientifi c Inc, Chatsworth, CA) is a hybrid device that combines the advantage of a balloon catheter with multicatheter brachytherapy. The ClearPath device consists of 6 expandable tubes around a central catheter that accepts the HDR iridium-192 source. These catheters can be adjusted by rotating a knob at the base of the device to conform to the lumpectomy cavity. After ClearPath catheter placement, a rubber sleeve is sutured to the patient and the base of the catheter is cut off, leaving only the catheters exposed. This avoids cumbersome exposed catheters (a frequent source of patient discomfort and complaint) and allows reduction in the received radiation skin dose without compromising target volume such as in situations where inadequate skin distance may preclude APBI with other techniques (MammoSite). 72 Because ClearPath is a relatively new clinical device, no clinical outcome data currently exist. Dosimetric comparisons of ClearPath technology with MammoSite therapy have demonstrated similar target volume coverage with increased normal tissue-sparing.
72,73
Strut-Adjusted Volume Implant
The Strut-Adjusted Volume Implant (SAVI) device (Cianna Medical Inc, Aliso Viejo, CA) is a single-entry, multiple-strutted catheter device that is inserted on an outpatient basis by a radiation oncologist under ultrasound guidance. The device consists of a central strut surrounded by 6 to 10 peripheral struts that can be expanded to fi t a lumpectomy cavity by simple rotation of a knob at the proximal end of the expansion device. 74, 75 The expansion of the struts provides a pressure fi t, securing the struts in place with expansion to fi ll the cavity. Computed tomography confi rmation of catheter placement is required prior to initiation of radiation therapy. Early experience with this device involving more than 100 patients with 21-month follow-up found the SAVI to be well tolerated, with only 2 symptomatic seromas, 2 patients with fat necrosis, and 1% recurrence observed. 76 In that series, 5% of the patients would have been ineligible for any balloon brachytherapy and 27% were ineligible specifi cally for MammoSite therapy due to inadequate skin-to-cavity distances.
Noninvasive APBI Techniques
3D Conformational Radiation Therapy 3D conformational external beam radiation therapy (3D-CRT), a noninvasive alternative to surgical APBI techniques, uses a linear accelerator-based treatment. Target volume planning is determined based on computed tomography of the lumpectomy cavity (confi rmed by postoperative changes, seroma cavity, or surgical clips if placed) with an additional safety margin of 1 cm to 2 cm. Because the breast is a mobile organ, a larger treatment area may be required to provide homogenous coverage of the target volume and avoid geographic miss. The homogenous, uniform target volume coverage applied by 3D-CRT is thought to result in a more favorable cosmetic outcome with less long-term fi brosis or fat necrosis than that observed with other APBI techniques. This technique utilizes four to fi ve tangentially oriented noncoplanar beams targeted to the tumor bed. 3D-CRT delivers 38.5 Gy within 1 week (3.85 Gy twice daily) based on the radiation dose used for the phase III National Surgical Adjuvant Breast and Bowel Project B-39/Radiation Therapy Oncology Group (NSABP/ RTOG) protocol.
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3D-CRT avoids the need for a second invasive surgical procedure and can be performed at most radiation centers. It is easily administered and reproducible, and it does not rely on the operator-dependent technical demands that other APBI alternatives may require. One disadvantage to 3D-CRT is that motion of the breast with normal respiration and daily setup variation requires a larger target treatment volume. The clinical target volume is defi ned as the visible postoperative tumor bed plus a 1-cm to 1.5-cm margin of surrounding normal tissue. This margin addresses the fact that a majority of local recurrences occur in the vicinity (within 1 cm to 2 cm) of the primary lesion. 12, 78, 79 Some have recommended prone positioning to minimize target tissue movement and avoid missing the planned target area during treatment. 80 Nevertheless, the planned treatment volume around the lumpectomy cavity is adjusted to account for breathing motion and differences in setup. 81 Chen et al 82 reported on the outcome of patients with stage I or II breast cancer who underwent treatment with 3D-CRT. 82 Ninety-four patients were treated with a median of 4.2 years of follow-up with an ipsilateral in-breast failure observed in 1.1% (1 recurrence), good cosmesis reported in 89%, and long-term fi brosis in 3% of patients. Results from the prospective RTOG-0319 trial treated 52 eligible patients of 58 enrolled and identifi ed similar results. 83 With a median follow-up of 4.5 years, the ipsilateral breast failure rate was an estimated 6%; two grade 3 toxicities were observed.
A variety of additional noninvasive partial breast irradiation techniques including intensity-modulated radiotherapy (IMRT), 84 volumetric-modulated arc therapy (VMAT), 85 continuous arc rotation of the couch (C-ARC), 86 Accuboost, 87, 88 and photon beam therapy 89 are currently under clinical investigation. Results are continuing to accrue with these techniques and will provide additional future information.
Intraoperative Radiotherapy Techniques
Intraoperative radiation therapy (IORT) is an especially attractive APBI treatment option in that it delivers a single dose at the time of initial surgery. Several centers have begun to investigate the utility of IORT for patients with low-risk, early-stage invasive cancers (ie, age > 60 years with T1 N0 ER-positive invasive ductal carcinoma), either as a boost to the tumor bed or as sole treatment after partial mastectomy. [90] [91] [92] Several IORT options are clinically available, including the Mobetron (IntraOp Medical Corp, Norcross, GA) 93 and Novac 7 (Hitesys, Aprilia, Italy) 94 devices, which employ electrons (megavoltage), and the Axxent and Intrabeam devices, which utilize a kilovoltage source. 
Axxent Electronic Brachytherapy
The Axxent Electronic Brachytherapy System (Xoft Inc, Fremont, CA) is a novel form of balloon-based brachytherapy that uses an electronic 50 kilo-voltage radiation source rather than an iridum-192 HDR source. 95 The catheter is a single lumen balloon catheter, similar to the MammoSite catheter, and contains two additional ports, one for evacuation of air or fl uid and the other for balloon insuffl ation. The X-ray source delivers radiation to the patient via a miniature X-ray tube inserted into the central lumen of the catheter. This approach is unique in that it avoids the need for an HDR after-loader unit or a shielded radiation room. This increases the potential applicability of this technology by making it more portable, and it can be administered intraoperatively as well. 95, 96 The Axxent electronic brachytherapy catheter was FDA-approved in 2006.
Axxent brachytherapy, compared to MammoSite, provides similar target volume coverage with increased normal tissue sparing. 97 Early clinical experience with Axxent technology has been associated with only transient short-term toxicity (erythema or blistering) and no adverse device-related events. 98 Because of the recent introduction of this novel technique, long-term clinical experience is currently lacking. Early single and multicenter results, however, have been generally favorable with good cosmesis demonstrated and without any recurrences observed.
96,99
Targeted Intraoperative Radiotherapy The Targeted Intraoperative Radiotherapy (TARGiT) trial opened in 2000 and randomized more than 2,200 women to post-lumpectomy whole breast irradiation vs a single IORT dose to the periphery of the tumor bed. 92 Compared with whole breast irradiation, IORT partial breast irradiation using the Intrabeam System (Carl Zeiss Surgical, Oberkochen, Germany) was found to be safe and effi cacious, with fewer radiotherapy-related complications and without a signifi cant difference in local recurrence at 4 years of followup (0.95% and 1.2%, respectively). The Intrabeam system delivers IORT from a source of low energy X-rays (50 kV maximum) using a spherical solid-state radio-applicator placed within the tumor bed following surgical extirpation. Phase II studies have also demonstrated safety and tolerability when targeted IORT is delivered as a boost alternative followed by standard whole breast external beam irradiation. 45, 100 The Intrabeam device was recently approved for clinical use in North America in low-risk, early-stage breast cancer patients, and a number of centers have adopted this technology. Use of the device at the Dorothy G. Hoefer Comprehensive Breast Center began in 2009 and at Moffi tt Cancer Center in January 2011 as among the fi rst North American centers to employ this method of APBI. We herein report on our early surgical experience at Moffi tt Cancer Center using the Intrabeam device as defi nitive therapy for a predefi ned low-risk patient population with earlystage invasive breast cancer.
Methods
A single-institution study approved by the institutional review board was performed on a prospectively maintained database of patients who underwent targeted intraoperative radiotherapy at the time of initial surgery for early-stage breast cancer. A multidisciplinary APBI pathway was developed based on ASTRO guidelines and was approved by a consensus panel of clinicians within the Department of Women's Oncology at Moffi tt Cancer Center consisting of breast-specifi c surgical oncologists, medical oncologists, radiation oncologists, radiologists, and pathologists.
Eligibility criteria included postmenopausal women greater than 60 years of age who were postmenopausal with ER-positive, invasive ductal histology. All patients included were breast conservation candidates with primary clinical tumors size < 3.1 cm, were clinically node negative, and had received no prior neoadjuvant treatment. Invasive tumors with limited lymphovascular invasion and/or HER2-positive disease on core needle biopsy were considered acceptable. Patients underwent informed consent discussion regarding the risk benefi ts and alternatives to IORT with the Intrabeam delivery system. IORT was planned for delivery at the time of initial surgery (partial mastectomy) using a predetermined applicator based on dimensions of the primary tumor and the breast excision specimen cavity. The duration of IORT in minutes (generally 15 to 25 minutes) was determined based on the chosen size of the radio-applicator to deliver 20 Gy of targeted radiation to the lumpectomy cavity. Intraoperative ultrasound was used to measure and confi rm a ≥ 1-cm skin-to-surface of applicator distance in superior, inferior, medial, and lateral dimensions relative to the radio-applicator. Subcutaneous tissue fl aps were created when necessary to obtain at least a 1-cm margin if needed. Skin was retracted at least 1 cm from the applicator surface-shaft interface using the Lone Star Retractor System (CooperSurgical Inc, Stafford, TX).
The sequence of surgery was to fi rst perform a sentinel node biopsy, if appropriate. While awaiting the touch preparation (hereafter "touch prep") analysis of the sentinel lymph node(s), the (needle-localized) partial mastectomy was performed. An intraoperative specimen radiograph was obtained and gross evaluation of the specimen was conducted for margin assessment. Any margin grossly less than 5 mm was reexcised intraoperatively at this initial surgery. IORT was then delivered as "intended" defi nitive therapy at the time of initial surgery if the sentinel lymph node was negative on touch prep analysis and the gross margins from tumor to inked surface were greater than 5 mm. Alternatively, if the patient had an excisional biopsy diagnosing her cancer, IORT was performed at the time of reexcision of margins for close (< 2 mm) microscopic margins. When fi nal pathology confi rmed histologically that all margins were negative, as well as the sentinel nodes if applicable, then no further radiation was given. Additionally, if on fi nal pathology, postpartial mastectomy with IORT, there was one focally close margin (< 2 mm), reexcision was not performed. However, if the fi nal pathology margin was positive or more than focally close to the margin, reexcision was required. If these subsequent reexcision margins were cancer-free, no further radiation treatment was recommended. However, if any reexcision margin specimens contained cancer, despite negative fi nal margins, those patients were treated with whole breast irradiation with the IORT replacing the external beam boost. Similarly, if the sentinel lymph node was positive at the time of initial surgery, IORT was delivered as a boost (and not as defi nitive therapy), and whole breast irradiation was subsequently recommended.
For patients who required adjuvant chemotherapy and/or whole breast irradiation after initial resection and delivery of IORT, chemotherapy was delivered prior to administration of whole breast irradiation. Patients with fi nal pathology specimens demonstrating extensive lymphovascular invasion or other adverse prognostic factors (extensive intraductal component, invasive lobular histology, HER2-positive) were offered whole breast irradiation on a case-by-case basis. All patients underwent unilateral digital mammography and focused breast ultrasound of the lumpectomy site at about the 6-month follow-up visit. The development of new calcifi cations or the presence of a seroma was noted by the interpreting radiologist. Postoperative physical examination fi ndings around the IORT site included skin contour, hyperemia, erythema, and palpable seroma. Descriptive statistics were recorded using SPSS software.
Results
Forty-two patients underwent targeted IORT with the Intrabeam delivery system at the time of breastconserving surgery. The median patient age was 71 years (range, 54 to 88 years). All patients treated were postmenopausal, 41 patients (98%) were ER-positive, and 39 patients (93%) were progesterone receptorpositive. Tumor location involved the upper outer quadrant in 28 patients (67%), upper inner quadrant in 4 (10%), central region in 6 (14%), lower outer quadrant in 3 patients (7%,) and lower inner quadrant in 1 patient (2%). Final pathology was invasive ductal carcinoma in 38 patients (91%), invasive lobular carcinoma in 2 patients (5%), DCIS in 1 patient (2%), and invasive mammary carcinoma in 1 patient (2%). Twenty-seven patients (64%) had associated DCIS within the excised specimen. Median invasive tumor size was 1.0 cm (range, 0.2 cm to 3.5 cm), with 18 patients (43%) having low-grade tumors, 23 patients (55%) with intermediate-grade tumors, and 1 patient (2%) with high-grade tumors. Sentinel lymph node status was available in 40 patients. One patient (2%) refused sentinel lymph node biopsy and the second patient underwent attempted axillary exploration after previously having ipsilateral breast conservation surgery with axillary dissection 10 years prior. Nodal status was microscopically negative (N0i-) in 36 patients (86%), and 4 (10%) had microscopically positive (N1) nodal involvement on fi nal pathology. No patient underwent completion axillary lymph node dissection (Table 4) .
All patients received a single dose of preoperative intravenous antibiotics and then underwent breastconserving surgery with sentinel lymph node biopsy followed by IORT using the Intrabeam device. An IORT dose of 20 Gy was delivered to all patients for a median IORT duration of 25 minutes (range, 15 to 30 minutes). IORT was administered using a 3-cm radio-applicator in 34 patients (81%) or a 3.5-cm radioapplicator in 8 patients (19%). Subcutaneous tissue fl aps were created in 21 patients (50%) to accommodate the radio-applicator within the tumor bed and maintain the appropriate skin-to-surface of applicator distance of > 1 cm. Median operative time for (needle localized) partial mastectomy, sentinel lymph node biopsy, and delivery of IORT was 119 minutes (range, 90 to 153 minutes). No patient received postoperative antibiotics upon discharge home from the recovery room.
Initial intraoperative gross/touch prep of margins was negative in 31 patients (74%), close (< 2 mm) in 7 patients (17%), and positive in 4 patients (10%). Twenty-eight patients (67%) underwent synchronous intraoperative excision of additional margins based on touch prep analysis or gross evaluation. Ten patients (24%) underwent subsequent reexcision for close (< 2 mm) or positive microscopic margins after lumpectomy. Final pathological margin was negative in 39 patients (93%) and focally close (< 2 mm) in the remaining 3 patients (7%). No patient underwent mastectomy in the treatment cohort (Table 5) .
Adjuvant whole breast irradiation was given to 8 patients (19%) due to the following factors: (1) 1 patient with a close fi nal margin and a positive sentinel lymph node biopsy, (2) 2 patients with negative margins but a positive sentinel lymph node biopsy on serial hematoxylin-eosin (H&E) staining who opted out of a complete axillary node dissection, (3) 3 patients with close margins, (4) 1 patient with invasive lobular histology on fi nal pathology, and (5) 1 patient who had and ipsilateral new primary who had previously undergone lumpectomy/axillary dissection/whole breast irradiation. The Oncotype DX assay (Genomic Health Inc, Redwood City, CA) to determine risk of recurrence was performed in 18 patients (43%) with a median recurrence score of 21 (range, 4 to 46). Two patients had their tumor specimen sent for Oncotype DX analysis but had insuffi cient tissue for RNA analysis to allow risk of recurrence determination. Five patients (12%) received adjuvant chemotherapy in addition to a planned aromatase inhibitor, while an aromatase inhibitor therapy alone was given to 34 patients (81%).
At a median of 15 days to fi rst postoperative examination (range, 8 to 50 days), 15 patients (36%) had evidence of IORT-related hyperemia/erythema on physical examination without requiring antibiotics, 14 (33%) had a palpable seroma, and 2 patients (5%) developed cellulitis, 1 requiring surgical drainage 9 days postoperatively. Five patients (12%) experienced postoperative complications: abscess requiring drainage (1), cellulitis (2), infected seroma requiring aspiration (1), and hematoma (1). Fourteen patients (50%) reached the 6-month follow-up mark (up to December 2011). Eleven patients underwent planned 6-month breast ultrasound, 9 of whom had sonographic evidence of seroma formation with a median seroma size of 3.4 cm (range, 1 cm to 4 cm). Six-month physical examination fi ndings included noninfectious localized hyperemia (4), asymptomatic palpable seroma (5), scar retraction (1), and cellulitis (1) . With a median follow-up of 3 months (range, 1 to 13 months), there were no local recurrences (Table 6 ).
Discussion
Initial experience using the Intrabeam delivery system originates from its application in treating metastatic brain metastases. 101, 102 This led others to explore additional application alternatives for other disease process. The rationale for delivery of partial breast irradiation with IORT or other techniques in breast cancer is based on the observation that a majority of local recurrences after breast conservation therapy occur within the vicinity of the primary tumor. 103 Initial phase II studies demonstrated IORT use in patients with low-risk breast cancers to be safe and feasible. 100 Furthermore, when given as a boost, IORT was associated with a low recurrence rate when compared to a conventional 5-to 6-week regimen with whole breast irradiation. 45 Results were recently reported from a prospective randomized phase III trial (TARGiT-A) conducted primarily in Europe and selected centers in North America, comparing targeted IORT with Intrabeam to whole breast irradiation. 92 This international multicenter, noninferiority trial demonstrated that IORT delivery with Intrabeam resulted in similarly low local recurrence rates compared to several weeks of whole breast irradiation for selected patients. One of the sentinel centers in North America using IORT (Dorothy G. Hoefer Breast Comprehensive Center) enrolled several patients in the TARGiT-A trial and observed no signifi cant difference in skin-related toxicity or pain requirements when compared to those not receiving IORT (separate internal review, R.H).
In the TARGiT-A trial, patients were selected as candidates for IORT if they had early-stage invasive breast cancers (generally T1 or T2 primary tumors, < 3.5 cm). 92 Fifty percent had tumors between 1 cm to 2 cm in size, with 14% having tumors > 2 cm. Our patient population tended to be older (median age 72.5 years) than those treated in the TARGiT-A trial and with a smaller tumor size. The median tumor size treated with IORT was 0.95 cm, with the largest tumor treated measuring 2 cm. Ninety-three percent of patients had invasive ductal histology while 1 patient had DCIS.
The technique describing the intraoperative delivery of IORT using the Intrabeam device has been previously described. 104 At Moffi tt Cancer Center, the administration of IORT with Intrabeam was found to be relatively simple to implement technically, with minimal addition to overall length of the operation. Initial reports noted that IORT administration added generally about 45 minutes of additional length to the operation. This compares favorably as far as overall time and cost savings when considering that a typical 6-week postoperative radiotherapy course involves 6 to 7 hours of radiotherapy room time with 30 to 60 hours of patient time. 103, 104 Moffi tt Cancer Center's total median operative time was 123 minutes. Considering that the length of IORT generally lasted 20 to 25 minutes, allowing also a few minutes for machine preparation, ultrasound assessment of skin to surface of applicator distance, potential creation of subcutaneous tissue fl aps, placement of the radio-applicator, and removal at the completion of IORT, the entire delivery process did not signifi cantly lengthen the entire duration of the operation. Furthermore, for the majority of patients who do not require additional radiotherapy or margin reexcision, the option of completing radiotherapy at the time of surgical excision is an attractive treatment alternative.
IORT with Intrabeam delivers 20 Gy of radiotherapy at the surface of the applicator, with 5 Gy to 6 Gy delivered at a distance of 1 cm from the applicator. 100 The relative biologic effectiveness (RBE) of low-energy photons modeled using the linearquadratic formula as a function of depth from the applicator surface demonstrates a higher RBE closer to the applicator surface compared to conventional fractionation, with a lower RBE at greater distances. 105 These models translate to a higher local control rate nearer to the applicator that partly compensates for reduced local control at greater distances and suggest that overall local control rates should be equivalent to conventionally fractionated radiotherapy up to 10 mm from the applicator surface.
At Moffi tt Cancer Center, other technical adjuncts were found to be useful during the administration of IORT to avoid skin-related toxicity. Maintaining a distance of at least 1 cm between the applicator and the nearest skin margin is important as multiple authors have reported skin-related complications when this distance is not maintained. 92 , 100 Wenz et al 106 observed the development of grade III fi brosis with hyperpigmentation and skin retraction in 1 patient treated when skin distance was kept < 5 mm from the applicator during treatment. Moffi tt Cancer Center utilized intraoperative ultrasound to ensure that a safe distance was maintained prior to the delivery of IORT (Table  5) . Lone Star tissue hooks (CooperSurgical Inc, Stafford, TX) placed circumferentially around the wound helped to maintain this distance. We also wrapped the neck of the applicator with a saline-soaked radiolucent sponge to decrease the dead space and minimize movement of the skin around the applicator during treatment. In some patients (68%), we created subcutaneous tissue fl aps (within the breast parenchyma, not the skin dermis) to accommodate better applicator placement, maximizing tissue apposition and breast cavity area coverage with the applicator. In certain situations (superfi cially oriented tumors), an ellipse of skin may need to be excised to accommodate the applicator device and avoid unintended skin overexposure. A tungsten-impregnated polyurethane sheet was utilized on the surface of all patients to protect the skin and surrounding tissues from radiation scatter. To save time, IORT was delivered after the partial mastectomy/sentinel lymph node biopsy had been performed. We did not initiate IORT until we were satisfi ed that margins were clear, reexcising a close or positive margin if necessary, before delivering the radiation dose. This allowed minimal interruption in the cadence of the procedure while awaiting touch prep analysis of the sentinel lymph node.
Initial postoperative physical examination fi ndings were mild, and the combined surgery with IORT was generally well tolerated in the Moffi tt Cancer Center experience. Forty-six percent of patients had evidence of localized hyperemia at initial postoperative visit. At 6-month follow-up (N = 14 as of December 2011), this was markedly reduced as only 14% had residual evidence of noninfectious hyperemia. Ten patients (36%) had evidence of an asymptomatic palpable seroma at fi rst postoperative visit. At Moffi tt Cancer Center, we performed a routine 6-month follow-up breast ultrasound to measure for residual seroma. Nine patients (32%) had ultrasound evidence of residual seroma present. On physical examination, however, only 5 patients (18%) had a palpable seroma appreciable at 6-month follow-up, all of which were asymptomatic. This fi nding was one of the major IORT-related toxicities observed within the TARGiT-A trial. Patients in the IORT arm were more likely to develop clinically signifi cant seroma that required 3 or more aspirations. 92 Only 1 patient required seroma aspiration. In that situation, the seroma became secondarily infected, was aspirated, and ultimately resolved after a short course of oral antibiotics. One patient developed an early postoperative methicillin-resistant Staphylococcus aureus (MRSA) abscess requiring operative drainage at postoperative day 9. Another patient who required whole breast irradiation after IORT developed delayed-onset cellulitis approximately 4 months after her procedure. She did not have evidence of cellulitis at her fi rst two postoperative visits. The toxicity ultimately resolved with oral antibiotic therapy alone. The timing of external beam radiation therapy after IORT is critical as those who receive additional whole breast irradiation within 36 days of IORT are more likely to develop late toxicity fi ndings characterized by fi brosis, retraction, or breast pain. 106 While Moffi tt Cancer Center did not specifi cally address "pain" as an endpoint, others have reported that IORT is not associated with increased risk of the development of persistent pain after breast cancer treatment when compared to external beam radiation therapy. 107 Pain was recorded at the Dorothy G. Hoefer Comprehensive Breast Center where 24 women having Intrabeam as the "boost" followed by standard whole breast irradiation were compared to 24 women having the "boost" and the whole breast radiation all as external beam following defi nitive surgery (personal communication, R. H., December 15, 2011) . Postoperative pain as reported by narcotic prescription use was not signifi cantly different between the two groups (mean 1.1 vs 0.5; P = .2). Other fi ndings were similar to the main TARGiT-A trial and Moffi tt Cancer Center's results. The median age in the Intrabeam group was 63 years (range, 44 to 80 years), and the median follow-up was 4 months. Six women had grade 1 skin erythema. No higher skin reactions were evident at 1 month following surgery. Two patients developed delayed infections of their seroma cavities 1 month following completion of the external beam regimen. The median seroma size of IORT-treated patients at 1 month was 24.0 cc (range, 4.9 cc to 190.0 cc), while the median seroma size for non-IORT patients was 2.4 cc (range, 0 cc to 14.3 cc; P < .01).
Unlike our counterparts in Virginia at the Dorothy G. Hoefer Comprehensive Breast Center, whole breast irradiation was given after targeted IORT to a total of only 4 patients (14%) at Moffi tt Cancer Center. Three patients (11%) had whole breast irradiation for a positive sentinel lymph node biopsy on fi nal pathology (one touch prep negative, the other with a single cluster on touch prep analysis, one touch prep positive). After counseling of the risks and benefi ts, all 3 patients opted not to undergo completion axillary lymph node dissection. Whole breast irradiation treatment fi elds were adjusted to include level I/II axillary lymph node regions. The remaining patient was treated with whole breast irradiation after IORT for a positive fi nal pathological margin after reexcision. Interestingly, in phase II reports of IORT given as a "boost" combined with external whole breast radiation therapy, patients with focal microscopic margins who did not undergo reexcision did not experience an increased local recurrence rate, possibly due to more accurate targeting and timeliness of treatment. 45 Although not a primary endpoint of this study due to limited follow-up, no recurrences were observed in this short treatment experience.
Conclusions
A variety of accelerated partial breast irradiation (APBI) techniques are available. The most appropriate treatment should be selected on an individual basis according to patient and clinician preference, institutional capabilities, and familiarity with the risk and benefi ts of the most common APBI techniques. At Moffi tt Cancer Center, while a variety of APBI methods are currently utilized, intraoperative radiation therapy (IORT) was found to be a suitable treatment alternative for highly selected patients with early-stage invasive breast cancers who meet the suitability criteria for accelerated partial breast irradiation. The technique is easily applied with only minimal increase in operative length. IORT can be intended for use as a boost followed by whole breast irradiation in situations of unfavorable histopathology. IORT-related toxicity is acceptable and avoids the time inconvenience of a 5-to 6-week postoperative course of whole breast irradiation, making it an attractive treatment alternative for a signifi cant group of patients.
